Señales en vivo de NOVO-B.CO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 10:50):

Stats
Volumen de hoy	874 296
Volumen promedio	2.74M
Capitalización de mercado	3 981.83B
EPS	DKK0 ( 2024-01-30 )
Próxima fecha de ganancias	( DKK5.38 ) 2024-05-01
Last Dividend	DKK0 ( N/A )
Next Dividend	DKK0 ( N/A )
P/E	47.52
ATR14	DKK0.561 (0.06%)

Volumen Correlación

Largo: 0.18 (neutral)

Corto: 0.07 (neutral)

Signal:(36.909) Neutral

Novo Nordisk A/S Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novo Nordisk A/S Correlación - Moneda/Commodity

-0.61
( weak negative )

-0.40
( neutral )

-0.54
( weak negative )

-0.52
( weak negative )

0.61
( weak )

-0.26
( neutral )

Novo Nordisk A/S Finanzas

Annual	2023
Ingresos:	DKK232.26B
Beneficio Bruto:	DKK196.50B (84.60 %)
EPS:	DKK18.67

FY	2023
Ingresos:	DKK232.26B
Beneficio Bruto:	DKK196.50B (84.60 %)
EPS:	DKK18.67

FY	2022
Ingresos:	DKK176.95B
Beneficio Bruto:	DKK148.51B (83.92 %)
EPS:	DKK24.51

FY	2021
Ingresos:	DKK140.80B
Beneficio Bruto:	DKK117.14B (83.20 %)
EPS:	DKK20.79

Financial Reports:

No articles found.

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Actualizaciones en tiempo real para Novo Nordisk A/S [NOVO-B.CO]

Upcoming Earnings Alert